LRMR Management Company Deerfield L.P. buys $30.0M worth of shares
Aug 05, 2025, 4:34 AM
0.00%
What does LRMR do
Larimar Therapeutics, based in Bala Cynwyd, Pennsylvania, focuses on developing novel therapeutics for mitochondrial disorders and Friedreich's ataxia using its cell penetrating peptide technology. Its lead candidate, nomlabofusp, aims to deliver essential protein frataxin to mitochondria for treating this rare disease.
Management Company Deerfield L.P. bought 9,375,000 shares of LRMR on 31 July at $3.20 per share, worth a total of $30.0M. They now own 9,538,945 LRMR shares, or a 5718% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.